ANI Pharmaceuticals (ANIP) Competitors

ANI Pharmaceuticals (NASDAQ:ANIP) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

Which has more volatility and risk, ANIP or ADMA?

ANI Pharmaceuticals has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.

Which has higher earnings and valuation, ANIP or ADMA?

ADMA Biologics has lower revenue, but higher earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$614.38M	2.26	-$18.52M	-$1.27	-50.39
ADMA Biologics	$426.45M	10.07	$197.67M	$0.85	21.15

Does the media favor ANIP or ADMA?

In the previous week, ANI Pharmaceuticals had 13 more articles in the media than ADMA Biologics. MarketBeat recorded 16 mentions for ANI Pharmaceuticals and 3 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.31 beat ANI Pharmaceuticals' score of 0.80 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer ANIP or ADMA?

ANI Pharmaceuticals presently has a consensus target price of $78.88, indicating a potential upside of 23.24%. ADMA Biologics has a consensus target price of $27.67, indicating a potential upside of 53.87%. Given ADMA Biologics' stronger consensus rating and higher possible upside, analysts clearly believe ADMA Biologics is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Do institutionals & insiders have more ownership in ANIP or ADMA?

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 12.7% of ANI Pharmaceuticals shares are owned by insiders. Comparatively, 3.7% of ADMA Biologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Is ANIP or ADMA more profitable?

ADMA Biologics has a net margin of 45.01% compared to ANI Pharmaceuticals' net margin of -3.12%. ADMA Biologics' return on equity of 47.16% beat ANI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	-3.12%	21.35%	7.52%
ADMA Biologics	45.01%	47.16%	30.51%

Summary

ADMA Biologics beats ANI Pharmaceuticals on 10 of the 16 factors compared between the two stocks.